332 related articles for article (PubMed ID: 33038760)
1. Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
Ray-Coquard I; Vanacker H; Le Saux O; Tredan O
EBioMedicine; 2020 Nov; 61():103046. PubMed ID: 33038760
[No Abstract] [Full Text] [Related]
2. PARP inhibitors in ovarian and other cancers.
Plummer R
Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
[No Abstract] [Full Text] [Related]
3. When in the treatment continuum to use PARP inhibition in ovarian cancer.
Mirza MR
Clin Adv Hematol Oncol; 2021 Feb; 19(2):84-86. PubMed ID: 33596189
[No Abstract] [Full Text] [Related]
4. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
5. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
6. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Klotz DM; Wimberger P
Arch Gynecol Obstet; 2020 Nov; 302(5):1087-1102. PubMed ID: 32833070
[TBL] [Abstract][Full Text] [Related]
7. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
8. PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations.
Vanacker H; Harter P; Labidi-Galy SI; Banerjee S; Oaknin A; Lorusso D; Ray-Coquard I
Cancer Treat Rev; 2021 Sep; 99():102255. PubMed ID: 34332292
[TBL] [Abstract][Full Text] [Related]
9. Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
Washington C; Gunderson CC; Moore KN
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):4-11. PubMed ID: 30451713
[TBL] [Abstract][Full Text] [Related]
10. PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.
Al Hadidi S; Aburahma A; Badami S; Upadhaya S
Oncol Res Treat; 2018; 41(4):226-235. PubMed ID: 29562224
[No Abstract] [Full Text] [Related]
11. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
12. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
14. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
[TBL] [Abstract][Full Text] [Related]
16. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
Tao M; Wu X
J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
[TBL] [Abstract][Full Text] [Related]
17. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
18. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
Miller RE; El-Shakankery KH; Lee JY
J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
[TBL] [Abstract][Full Text] [Related]
20. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
